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Background
Metaplastic carcinoma of the breast (MCB) is a rare neo-
plasm, described in approximately 1% of all breast carci-
nomas. MCB is associated with poor prognosis and
correlated with a high recurrence rate and visceral metas-
tases. MCB is generally hormonal receptor-negative; spe-
cific treatments are not well defined. The objective of this
study was to describe the clinical and pathological fea-
tures of MCB.
Materials and methods
We included all the patients with diagnosis of MCB,
treated in Instituto Nacional de Cancerología (INCan) of
México City during the period from 1995 to 2005; all
cases had histopathological confirmation by two patholo-
gist. Clinical information, pathological features of the
tumor and survival information were collected; descrip-
tive analysis was done.
Results
From 1995 to 2005 the Instituto Nacional de Cancerolo-
gia attended 6,610 breast cancer cases; during this period
we found 40 (0.6%) cases of MCB, all of them were
female with a mean age of 47.9 years old (24–74). Based
on the WHO classification, 20 cases were purely epithelial
and 20 were mixed. Of purely epithelial cases, 8 (20%)
were squamous, 9 (22.5%) spindle cell and 3 (7.5%) ade-
nosquamous. Mixed cases with chondroid metaplasia,
osseous metaplasia and carcinosarcoma, were 15
(37.5%), 3 (7.5%) and 2 (5%) patients, respectively. The
right breast were more affected than left (58% vs. 42%).
Clinical stages I, II and III were 5%, 35% and 52.5%,
respectively; no stage IV were documented. All patients
but 2 underwent surgery treatment. Relapse occurred in
10 cases (30.3%); recurrence sites were 2 (20%) local and
8 (80%) distant, frequently the bone. Overall survival was
45.2 months. Table 1 shows clinical and pathological fea-
tures between purely epithelial and mixed types of MCB.
Conclusion
The prevalence of MCB in INCan from 1995 to 2005 is
<1% (0.6%), with the same distribution between purely
epithelial and mixed types. Patients with mixed MCB
tended to be younger, with larger tumors, and less survival
than the purely epithelial group. Clinical stage, type of
surgery, systemic treatment, adjuvant treatment and recur-
rence where similar between both different histological
types.
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Table 1: Clinical and pathological features between purely epithelial and mixed epithelial MCB.
All cases Purely epithelial Mixed epithelial and mesenchymal
Mean age (years) (n = 40) 47.9 49.4 46.4
Breast side (n = 38)
Right 22 (58%) 10 (52.6%) 12 (63.1%)
Left 16 (42%) 9 (47.3%) 7 (36.8%)
Mean tumor size (cm) 7.16 (1.8–40) 5.79 (2–11) 8.31 (1.8–40)
Clinical stage
I 2 (5%) 0 2 (10.5%)
II 14 (35%) 8 (42.1%) 6 (31.5%)
III 21 (52.5%) 10 (52.6%) 11 (57.9%)
Non-classifiable 3 (7.5%)
Outcome (n = 33)
No relapse 20 (60.6%)
Relapse 10 (30.3%)
Progression of disease 3 (9.1%)
Recurrence site
Local 2 (20%) 1 (20%) 1 (20%)
Distant 8 (80%) 4 (80%) 4 (80%)
Overall survival (months) 45.2 49.9 40.5